Clopidogrel monotherapy was shown to be non-inferior to extended dual antiplatelet therapy (DAPT) with clopidogrel and aspirin for net adverse clinical events at 24 months among patients at high risk for ischaemic events after implantation of a drug-eluting stent, results of the A-CLOSE trial presented at the European Society of Cardiology (ESC) 2026 congress (28–31 […] The post ESC 2026: Clopidogrel monotherapy non-inferior to extended DAPT in patients at high ischaemic risk appeared first on Cardiovascular News .